Department of Pain Medicine, BG University Hospital Bergmannsheil GmbH, Ruhr-University Bochum, Bochum, Germany.
Center of Biomedicine and Medical Technology Mannheim CBTM, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.
Pain. 2017 Aug;158(8):1446-1455. doi: 10.1097/j.pain.0000000000000935.
In a recent cluster analysis, it has been shown that patients with peripheral neuropathic pain can be grouped into 3 sensory phenotypes based on quantitative sensory testing profiles, which are mainly characterized by either sensory loss, intact sensory function and mild thermal hyperalgesia and/or allodynia, or loss of thermal detection and mild mechanical hyperalgesia and/or allodynia. Here, we present an algorithm for allocation of individual patients to these subgroups. The algorithm is nondeterministic-ie, a patient can be sorted to more than one phenotype-and can separate patients with neuropathic pain from healthy subjects (sensitivity: 78%, specificity: 94%). We evaluated the frequency of each phenotype in a population of patients with painful diabetic polyneuropathy (n = 151), painful peripheral nerve injury (n = 335), and postherpetic neuralgia (n = 97) and propose sample sizes of study populations that need to be screened to reach a subpopulation large enough to conduct a phenotype-stratified study. The most common phenotype in diabetic polyneuropathy was sensory loss (83%), followed by mechanical hyperalgesia (75%) and thermal hyperalgesia (34%, note that percentages are overlapping and not additive). In peripheral nerve injury, frequencies were 37%, 59%, and 50%, and in postherpetic neuralgia, frequencies were 31%, 63%, and 46%. For parallel study design, either the estimated effect size of the treatment needs to be high (>0.7) or only phenotypes that are frequent in the clinical entity under study can realistically be performed. For crossover design, populations under 200 patients screened are sufficient for all phenotypes and clinical entities with a minimum estimated treatment effect size of 0.5.
在最近的一项聚类分析中,根据定量感觉测试结果,发现周围神经病理性疼痛患者可分为 3 种感觉表型,主要表现为感觉缺失、感觉功能正常伴轻度热痛觉过敏和/或痛觉过敏,或感觉丧失伴轻度触觉痛觉过敏和/或痛觉过敏。在这里,我们提出了一种将个体患者分配到这些亚组的算法。该算法是非确定性的,即一个患者可以被分到多个表型,并且可以将神经病理性疼痛患者与健康受试者区分开来(敏感性:78%,特异性:94%)。我们评估了痛性糖尿病周围神经病(n=151)、痛性周围神经损伤(n=335)和带状疱疹后神经痛(n=97)患者人群中每种表型的频率,并提出了需要筛查的研究人群样本量,以达到足以进行表型分层研究的亚人群大小。在糖尿病性多发性神经病中最常见的表型是感觉缺失(83%),其次是机械性痛觉过敏(75%)和热痛觉过敏(34%,注意百分比是重叠的,不是相加的)。在周围神经损伤中,频率分别为 37%、59%和 50%,在带状疱疹后神经痛中,频率分别为 31%、63%和 46%。对于平行研究设计,要么治疗的估计效果需要很大(>0.7),要么只能在研究中的临床实体中频繁出现的表型才能实际进行。对于交叉设计,筛选的患者人数少于 200 人,对于所有表型和临床实体,最小估计治疗效果大小为 0.5,就足够了。